Share

June 2021; 11 (3) Research

Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination

Zachary A. Marcum, Ching-Yuan Chang, Douglas Barthold, Holly M. Holmes, Wei-Hsuan Lo-Ciganic
First published May 29, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000870
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
70

Share

Article Information

vol. 11 no. 3 181-187
DOI: 
https://doi.org/10.1212/CPJ.0000000000000870
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received January 3, 2020
  • Accepted March 5, 2020
  • First Published May 29, 2020.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Zachary A. Marcum, PharmD, PhD,
    2. Ching-Yuan Chang, MS,
    3. Douglas Barthold, PhD,
    4. Holly M. Holmes, MD, MS and
    5. Wei-Hsuan Lo-Ciganic, MSPharm, MS, PhD
  1. Zachary A. Marcum, PharmD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) AHRQ, K12HS022982, mentored PI, 2016-2019, (2) NIA, K76AG059929, mentored PI, 2019-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ching-Yuan Chang, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Douglas Barthold, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHLBI - R01HL126804 - Value of Information Methods for NHLBI Trails, 2015-2019 Kaiser/NIH - R01HL130462 Effectiveness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Disease (VSH in Cardio Disease). 2016-2020 NIH - R01 MH National Institutes of Health R01MH121424-01A1, “Acceptability of sustained-release antiretrovirals for treatment in the US and sub-Saharan Africa,” (R01, PI: Susan Graham). 2019-2024, Role: Co-Investigator NHLBI - 1OT3HL152448-01, “Model for Economic Analysis of Sickle cell cURE (MEASURE)” 07/01/2019 – 06/30/2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Holly M. Holmes, MD, MS and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Health Care Services Corporation Affordability Cures Initiative

    Research Support, Government Entities:

    1. (1) National Center for the Advancement of Translational Sciences, 1UL1TR003167, Core Lead, (2) Cancer Prevention and Research Institute of Texas RP160674, collaborator

    Research Support, Academic Entities:

    1. (1) UTHealth McGovern Medical School Institutional Scholars Award

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Wei-Hsuan Lo-Ciganic, MSPharm, MS, PhD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIDA, 1R01DA044985, Consortium PI, 2017-2020, (2) NIA, 1R03MH114503, Co-I, 2017-2020, (3) Richard King Mellon Foundation, N/A, Multi-PI, 2017-2020, (4) 1R21AG060308-01A1, PI, 2019-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Pharmacy (ZAM, DB), University of Washington, Seattle; Department of Pharmaceutical Outcomes and Policy (C-YC, W-HL-C), Center for Drug Evaluation and Safety (C-YC, W-HL-C), College of Pharmacy, University of Florida, Gainesville; and Division of Geriatric and Palliative Medicine (HMH), The University of Texas Health Science Center at Houston, McGovern Medical School.
  1. Correspondence
    Dr. Marcum zmarcum{at}uw.edu

Article usage

Article usage: May 2020 to October 2023

AbstractFullPdfSource
May 20204302Highwire
Jun 2020215012Highwire
Jul 20205000Highwire
Aug 20205002Highwire
Sep 20203003Highwire
Oct 20202501Highwire
Nov 20201802Highwire
Dec 202010202Highwire
Jan 20213300Highwire
Feb 20214700Highwire
Mar 20213001Highwire
Apr 20211800Highwire
May 20212800Highwire
Jun 20216873417Highwire
Jul 202119594Highwire
Aug 202111491Highwire
Sep 20219912Highwire
Oct 20218533Highwire
Nov 20217112Highwire
Dec 20217121Highwire
Jan 20226920Highwire
Feb 20229300Highwire
Mar 20227500Highwire
Apr 20224310Highwire
May 20225900Highwire
Jun 20225313Highwire
Jul 20225123Highwire
Aug 20226601Highwire
Sep 20224902Highwire
Oct 20225211Highwire
Nov 20228100Highwire
Dec 20224610Highwire
Jan 20234701Highwire
Feb 20234200Highwire
Mar 20233511Highwire
Apr 20233510Highwire
May 20232100Highwire
Jun 20231901Highwire
Jul 20233201Highwire
Aug 2023510Highwire
Sep 20234711Highwire
Oct 20234400Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles